Information Provided By: 
Fly News Breaks for June 17, 2019
FOLD
Jun 17, 2019 | 07:13 EDT
H.C. Wainwright analyst Debjit Chattopadhyay started Amicus Therapeutics with a Buy rating and $18 price target. The analyst belies AT-GAA is a potentially superior alternative to Lumizyme. The ongoing Propel Phase 3 program is likely to deliver superiority over conventional enzyme replacement therapies, positioning Amicus with a shot at a $1B-plus lysosomal storage disorders franchise in 2025, Chattopadhyay tells investors in a research note.
News For FOLD From the Last 2 Days
There are no results for your query FOLD
